復星醫藥AH股齊創歷史新高 新冠疫苗“復必泰”上市將近
格隆匯7月21日丨復星醫藥AH大幅拉昇,A股一度漲超8%報81.3元,H股一度漲超6%報72.05港元,均創歷史新高;最新總市值超1600億人民幣。復星醫藥7月14日曾表示,中國國家藥監局對mRNA新冠疫苗“復必泰”的審定工作已基本完成,專家評審已通過,目前正加緊進行行政審批階段,有望很快成為國內首個mRNA新冠疫苗。7月18日,最新一批約86萬劑”復必泰”疫苗已運抵香港。一週前的7月12日,復星醫藥公吿,控股子公司復興實業與台積電、鴻海、永齡基金會和裕利醫藥簽訂協議,將向對方銷售合計1000萬劑mRNA新冠疫苗。實際上,早在今年1月和2月,香港和澳門先後批准,分別向復星醫藥訂購了750萬劑和40萬劑mRNA新冠疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.